NEWS
[Retail Market] Market Analysis Report on the "Ibuprofen" Variety of Antipyretic, Analgesic, and Anti-inflammatory Drugs
Capsules are the main dosage form of the "Ibuprofen" variety, and their market share in retail pharmacies has been increasing year by year.
Capsules are the main dosage form of the "Ibuprofen" variety, and their share in retail pharmacies has been increasing year by year (52% in 2023 → 58% in 2024 → 66% in Jan-Jun 2025). Sales in June 2025 exceeded 170 million yuan, a year-on-year increase of 13%; next is the solution form, whose share has decreased to 23% in 2025, with sales of 70 million yuan in June 2025.
The average store order index for ibuprofen solutions, tablets, and granules in retail pharmacies nationwide generally shows a fluctuating downward trend, while the average store order index for capsules has slightly increased; influenced by seasonal and flu factors, overall ibuprofen sales peak in winter (especially January).
The average store sales of ibuprofen capsules across provinces nationwide are generally at a high level, with most provinces' sales close to 6,000 yuan, showing small regional differences and minor fluctuations in growth rates, indicating overall stability; in contrast, ibuprofen solutions, tablets, and granules show larger regional differences, with many provinces experiencing negative growth and continuous sales decline.
The demographic distribution of ibuprofen capsules and tablets tends to be consistent, with female and male consumers aged 36-45 accounting for 27%; ibuprofen solutions and granules are mostly used by females aged 26-45, possibly related to mothers, accounting for 42% and 37% respectively.
Per capita consumption of ibuprofen capsules is positively correlated with age; high per capita consumption of ibuprofen solutions is concentrated in the core consumer group aged 26-45, while high per capita consumption of ibuprofen tablets is found in younger age groups.
The medicines commonly purchased together with ibuprofen capsules and tablets are similar, mainly including amoxicillin capsules, artificial bezoar metronidazole capsules, cold remedy granules, compound paracetamol and amantadine tablets/capsules, and minor bupleurum granules; for ibuprofen solutions and granules, the top co-purchased item is pediatric paracetamol and chlorpheniramine granules, related to children's cold and fever.
Hot news
Shengnuo Bio has signed a strategic agreement with a Brazilian "Belt and Road" institution to cooperate on the supply of peptide APIs, technology exchange, and market channel development, with a focus on promoting GLP-1 class APIs such as Semaglutide and Tirzepatide in the Brazilian market. This collaboration marks the extension of the company's overseas presence into the core South American market and provides a practical pathway for China-Brazil biomedical cooperation under the "Belt and Road" framework.
2025-12-08
The 93rd API China kicked off successfully in Chongqing on November 12, with Shengnuo Biopharm (Booth N5 Hall 5L25) getting off to a strong start on the first day. The exhibition floor was buzzing with professional exchanges, as the company's demonstration of its integrated, end-to-end capabilities in peptide APIs and CDMO services attracted numerous industry professionals for in-depth discussions and garnered widespread recognition. The exhibition is still ongoing, and we sincerely invite colleagues from across the industry to visit our booth to continue the dialogue and explore collaborative opportunities.
2025-11-12
Chengdu Shengnuo Biopharm sincerely invites you to attend the 93rd China International Pharmaceutical Raw Materials, Intermediates, Packaging, and Equipment Trade Fair (API China 2025). Join us from November 12–14, 2025, at Booth No. 5L25, Hall N5, Chongqing International Expo Center, as we explore cutting-edge technologies and collaboration opportunities in the peptide sector.
2025-11-11
October 30, 2025 – Chengdu Shengnuo Biopharm Co., Ltd. held the project commencement ceremony in Dayi Economic Development Zone, marking the official start of construction for the Semaglutide, Tirzepatide, and other peptide Active Pharmaceutical Ingredient (API) industrialization base project.
2025-10-31